In almost all of the solid tumor cell lines (except for the few which would be discussed here) and myeloid derived cancer cell lines (AML, n = 31; blast phase CML, n = 12; CML, n = 2; essential thrombocythaemia, n = 1), less than 50–100 BCR/TCR reads were detected in the dominant rearrangement (CPM < 0.5). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.